Genmab Announces Sale of Manufacturing Facility to Baxter

Genmab Announces Sale of Manufacturing Facility to Baxter

Company Announcement

  *Genmab sells manufacturing facility to Baxter Healthcare Corporation
  *Genmab receives USD 10 million

COPENHAGEN, Denmark, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today the signing and closing of an agreement with
Baxter Healthcare Corporation for the sale of Genmab's non-plasma-derived
antibody manufacturing facility, located in Brooklyn Park, Minnesota, USA, for
USD 10 million. Under the terms of the agreement Genmab receives the USD 10
million (approximately DKK 57 million) in cash and Baxter acquires the
facility, land, and equipment at the Brooklyn Park site. Baxter will offer
employment to the 23 employees currently supporting the facility.

"We have delivered on our commitment to execute the sale of the antibody
manufacturing facility in the first quarter of this year and are very pleased
that Baxter acquired the facility, including the 23 employees who have
maintained the facility to such a high standard," said Jan van de Winkel,
Ph.D., Chief Executive Officer of Genmab.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^(r); the
Y-shaped Genmab logo^(r); HuMax^(r); HuMax-CD20^(r); DuoBody^(r), HexaBody^TM
and UniBody^(r). Arzerra^(r) is a trademark of GlaxoSmithKline.

Company Announcement no. 04
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

CONTACT:  Rachel Curtis Gravesen, Senior Vice President
          Investor Relations & Communications
          T: +45 33 44 77 20
          M: +45 25 12 62 60
          E: r.gravesen@genmab.com
 
Press spacebar to pause and continue. Press esc to stop.